Prelude Therapeutics (PRLD): CEO bought ~$34K
Krishna Vaddi, CEO at Prelude Therapeutics, bought ~$34K of Prelude Therapeutics shares.
- ~$34K
- Approx. value · 48K sh @ $0.7104
- 1.21M
- Holds after · shares reported
- Traded
- Mar 12, 2025
- Filed
- Mar 14, 2025
What stands out in this filing
- The purchase added 4.1% to the shares this insider held before it; the filing reports 1,214,775 shares afterwards.
- 47,500 shares at an average of $0.7104 each, as reported on the form.
- The first open-market purchase by this insider in 3 months.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 12, 2025 · this disclosureInsiderCEO purchased ~$34K of PRLD shares in the open market
What came next
- Mar 13, 2025InsiderCEO purchased ~$36K of PRLD shares in the open market
- Mar 14, 2025InsiderCEO purchased ~$23K of PRLD shares in the open market
- Mar 17, 2025InsiderCEO purchased ~$6.8K of PRLD shares in the open market
- Mar 20, 2025InsiderCEO purchased ~$4K of PRLD shares in the open market
- Mar 21, 2025InsiderCEO purchased ~$11K of PRLD shares in the open market
- Mar 25, 2025InsiderCEO purchased ~$467K of PRLD shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Prelude Therapeutics
OQRO holds no insider, Congress, fund or contract record for Prelude Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PRLD page.
Other recent filings by Krishna Vaddi, CEO
- SEC Form 4 at Prelude Therapeutics (PRLD)Mar 27, 2025
- SEC Form 4 at Prelude Therapeutics (PRLD)Mar 24, 2025
- SEC Form 4 at Prelude Therapeutics (PRLD)Mar 24, 2025
- SEC Form 4 at Prelude Therapeutics (PRLD)Mar 18, 2025
- SEC Form 4 at Prelude Therapeutics (PRLD)Mar 18, 2025
The full history of Krishna Vaddi, CEO is on the profile page.
How this filing works
Explore the data
Common questions
Which Prelude Therapeutics (PRLD) insider traded, and how much?
Krishna Vaddi, CEO at Prelude Therapeutics, bought ~$34K of Prelude Therapeutics shares. 48K shares at $0.71, open market.
When did it happen, and when was it made public?
Traded: Mar 12, 2025. Filed: Mar 14, 2025. That is 2 days between the two dates.
What stands out in this filing?
The purchase added 4.1% to the shares this insider held before it; the filing reports 1,214,775 shares afterwards. 47,500 shares at an average of $0.7104 each, as reported on the form. The first open-market purchase by this insider in 3 months.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
Does this mean PRLD stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Prelude Therapeutics
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 4Mar 27, 2025
- SEC Form 4Mar 24, 2025
- SEC Form 4Mar 24, 2025
- SEC Form 4Mar 18, 2025
Everything OQRO holds on this company is on its PRLD page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
